Literature DB >> 23658446

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Pinghuang Liu1, Nicole L Yates, Xiaoying Shen, Mattia Bonsignori, M Anthony Moody, Hua-Xin Liao, Youyi Fong, S Munir Alam, R Glenn Overman, Thomas Denny, Guido Ferrari, Christina Ochsenbauer, John C Kappes, Victoria R Polonis, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Supachai Rerks-Ngarm, David C Montefiori, Peter Gilbert, Nelson L Michael, Jerome H Kim, Barton F Haynes, Georgia D Tomaras.   

Abstract

The detailed examination of the antibody repertoire from RV144 provides a unique template for understanding potentially protective antibody functions. Some potential immune correlates of protection were untested in the correlates analyses due to inherent assay limitations, as well as the need to keep the correlates analysis focused on a limited number of endpoints to achieve statistical power. In an RV144 pilot study, we determined that RV144 vaccination elicited antibodies that could bind infectious virions (including the vaccine strains HIV-1 CM244 and HIV-1 MN and an HIV-1 strain expressing transmitted/founder Env, B.WITO.c). Among vaccinees with the highest IgG binding antibody profile, the majority (78%) captured the infectious vaccine strain virus (CM244), while a smaller proportion of vaccinees (26%) captured HIV-1 transmitted/founder Env virus. We demonstrated that vaccine-elicited HIV-1 gp120 antibodies of multiple specificities (V3, V2, conformational C1, and gp120 conformational) mediated capture of infectious virions. Although capture of infectious HIV-1 correlated with other humoral immune responses, the extent of variation between these humoral responses and virion capture indicates that virion capture antibodies occupy unique immunological space.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23658446      PMCID: PMC3700223          DOI: 10.1128/JVI.02737-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

2.  Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.

Authors:  Mattia Bonsignori; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Lynn Morris; Elin Gray; Dawn J Marshall; John A Crump; Saidi H Kapiga; Noel E Sam; Faruk Sinangil; Marie Pancera; Yang Yongping; Baoshan Zhang; Jiang Zhu; Peter D Kwong; Sijy O'Dell; John R Mascola; Lan Wu; Gary J Nabel; Sanjay Phogat; Michael S Seaman; John F Whitesides; M Anthony Moody; Garnett Kelsoe; Xinzhen Yang; Joseph Sodroski; George M Shaw; David C Montefiori; Thomas B Kepler; Georgia D Tomaras; S Munir Alam; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

3.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

4.  Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.

Authors:  Elin S Gray; M Anthony Moody; Constantinos Kurt Wibmer; Xi Chen; Dawn Marshall; Joshua Amos; Penny L Moore; Andrew Foulger; Jae-Sung Yu; Bronwen Lambson; Salim Abdool Karim; John Whitesides; Georgia D Tomaras; Barton F Haynes; Lynn Morris; Hua-Xin Liao
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

5.  Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.

Authors:  Pinghuang Liu; R Glenn Overman; Nicole L Yates; S Munir Alam; Nathan Vandergrift; Yue Chen; Frederik Graw; Stephanie A Freel; John C Kappes; Christina Ochsenbauer; David C Montefiori; Feng Gao; Alan S Perelson; Myron S Cohen; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

6.  Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.

Authors:  Christina Ochsenbauer; Tara G Edmonds; Haitao Ding; Brandon F Keele; Julie Decker; Maria G Salazar; Jesus F Salazar-Gonzalez; Robin Shattock; Barton F Haynes; George M Shaw; Beatrice H Hahn; John C Kappes
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

7.  Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Authors:  Georgia D Tomaras; James M Binley; Elin S Gray; Emma T Crooks; Keiko Osawa; Penny L Moore; Nancy Tumba; Tommy Tong; Xiaoying Shen; Nicole L Yates; Julie Decker; Constantinos Kurt Wibmer; Feng Gao; S Munir Alam; Philippa Easterbrook; Salim Abdool Karim; Gift Kamanga; John A Crump; Myron Cohen; George M Shaw; John R Mascola; Barton F Haynes; David C Montefiori; Lynn Morris
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.

Authors:  M Anthony Moody; Ruijun Zhang; Emmanuel B Walter; Christopher W Woods; Geoffrey S Ginsburg; Micah T McClain; Thomas N Denny; Xi Chen; Supriya Munshaw; Dawn J Marshall; John F Whitesides; Mark S Drinker; Joshua D Amos; Thaddeus C Gurley; Joshua A Eudailey; Andrew Foulger; Katherine R DeRosa; Robert Parks; R Ryan Meyerhoff; Jae-Sung Yu; Daniel M Kozink; Brice E Barefoot; Elizabeth A Ramsburg; Surender Khurana; Hana Golding; Nathan A Vandergrift; S Munir Alam; Georgia D Tomaras; Thomas B Kepler; Garnett Kelsoe; Hua-Xin Liao; Barton F Haynes
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

10.  International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

Authors:  Daniel A Ozaki; Hongmei Gao; Christopher A Todd; Kelli M Greene; David C Montefiori; Marcella Sarzotti-Kelsoe
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

View more
  46 in total

Review 1.  Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Authors:  George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

Review 2.  Progress in HIV vaccine development.

Authors:  Denise C Hsu; Robert J O'Connell
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

Review 3.  HIV-1 vaccines: challenges and new perspectives.

Authors:  Jean-Louis Excler; Merlin L Robb; Jerome H Kim
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

4.  Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.

Authors:  Pinghuang Liu; Latonya D Williams; Xiaoying Shen; Mattia Bonsignori; Nathan A Vandergrift; R Glenn Overman; M Anthony Moody; Hua-Xin Liao; Daniel J Stieh; Kerrie L McCotter; Audrey L French; Thomas J Hope; Robin Shattock; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

5.  Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Authors:  Paul A Goepfert; Marnie L Elizaga; Kelly Seaton; Georgia D Tomaras; David C Montefiori; Alicia Sato; John Hural; Stephen C DeRosa; Spyros A Kalams; M Juliana McElrath; Michael C Keefer; Lindsey R Baden; Javier R Lama; Jorge Sanchez; Mark J Mulligan; Susan P Buchbinder; Scott M Hammer; Beryl A Koblin; Michael Pensiero; Chris Butler; Bernard Moss; Harriet L Robinson
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

6.  Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Authors:  Andrew J Gartland; Sue Li; John McNevin; Georgia D Tomaras; Raphael Gottardo; Holly Janes; Youyi Fong; Daryl Morris; Daniel E Geraghty; Gustavo H Kijak; Paul T Edlefsen; Nicole Frahm; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Jodie P Goodridge; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; John Sidney; Alessandro Sette; Susan Zolla-Pazner; David Montefiori; M Juliana McElrath; James I Mullins; Jerome H Kim; Peter B Gilbert; Tomer Hertz
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

7.  Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.

Authors:  Agnes-Laurence Chenine; Melanie Merbah; Lindsay Wieczorek; Sebastian Molnar; Brendan Mann; Jenica Lee; Anne-Marie OʼSullivan; Meera Bose; Eric Sanders-Buell; Gustavo H Kijak; Carolina Herrera; Robert McLinden; Robert J OʼConnell; Nelson L Michael; Merlin L Robb; Jerome H Kim; Victoria R Polonis; Sodsai Tovanabutra
Journal:  J Acquir Immune Defic Syndr       Date:  2018-07-01       Impact factor: 3.731

8.  Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Authors:  LaTonya D Williams; Gilad Ofek; Sebastian Schätzle; Jonathan R McDaniel; Xiaozhi Lu; Nathan I Nicely; Liming Wu; Caleb S Lougheed; Todd Bradley; Mark K Louder; Krisha McKee; Robert T Bailer; Sijy O'Dell; Ivelin S Georgiev; Michael S Seaman; Robert J Parks; Dawn J Marshall; Kara Anasti; Guang Yang; Xiaoyan Nie; Nancy L Tumba; Kevin Wiehe; Kshitij Wagh; Bette Korber; Thomas B Kepler; S Munir Alam; Lynn Morris; Gift Kamanga; Myron S Cohen; Mattia Bonsignori; Shi-Mao Xia; David C Montefiori; Garnett Kelsoe; Feng Gao; John R Mascola; M Anthony Moody; Kevin O Saunders; Hua-Xin Liao; Georgia D Tomaras; George Georgiou; Barton F Haynes
Journal:  Sci Immunol       Date:  2017-01-27

9.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

10.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.